Microsoft is ending support for Access 2016/2019 on October 14, 2025. Here are the bug fixes in the September 2025 update & ...
The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback